Artal Group Sa Has Raised Acceleron Pharma INC (XLRN) Stake by $66.70 Million as Share Value Rose

Acceleron Pharma Inc. (NASDAQ:XLRN) LogoInvestors sentiment increased to 1.83 in Q1 2019. Its up 0.72, from 1.11 in 2018Q4. It improved, as 14 investors sold XLRN shares while 34 reduced holdings. 28 funds opened positions while 60 raised stakes. 46.76 million shares or 10.00% more from 42.51 million shares in 2018Q4 were reported. Fiera Cap Corp owns 33,870 shares. Ameritas Inv Prns has 0.01% invested in Acceleron Pharma Inc. (NASDAQ:XLRN). California State Teachers Retirement Systems holds 0.01% of its portfolio in Acceleron Pharma Inc. (NASDAQ:XLRN) for 66,706 shares. Geller Advsr Llc invested in 0.35% or 18,750 shares. Comerica National Bank reported 0.01% in Acceleron Pharma Inc. (NASDAQ:XLRN). 4,700 are owned by Cubist Systematic Strategies Limited Liability Corp. Prudential Fin, a New Jersey-based fund reported 4,610 shares. Wells Fargo & Mn holds 35,259 shares. Amer Century Inc holds 94,276 shares. Pictet Asset Limited invested in 0.03% or 284,624 shares. Jasper Ridge Prtnrs Lp owns 12,498 shares for 0.02% of their portfolio. The Vermont-based Manchester Capital Mgmt Limited Com has invested 0% in Acceleron Pharma Inc. (NASDAQ:XLRN). Smith Asset Management Grp Ltd Partnership holds 0% or 840 shares in its portfolio. Jpmorgan Chase invested in 0% or 74,287 shares. Natixis owns 5,680 shares for 0% of their portfolio.

Since June 14, 2019, it had 1 insider purchase, and 0 sales for $190,250 activity.

Artal Group Sa increased its stake in Acceleron Pharma Inc (XLRN) by 725% based on its latest 2019Q1 regulatory filing with the SEC. Artal Group Sa bought 1.45 million shares as the company’s stock rose 9.20% . The institutional investor held 1.65M shares of the biological products (no diagnostic substances) company at the end of 2019Q1, valued at $76.84 million, up from 200,000 at the end of the previous reported quarter. Artal Group Sa who had been investing in Acceleron Pharma Inc for a number of months, seems to be bullish on the $2.38B market cap company. The stock decreased 0.75% or $0.34 during the last trading session, reaching $45.02. About 119,085 shares traded. Acceleron Pharma Inc. (NASDAQ:XLRN) has risen 4.00% since August 15, 2018 and is uptrending. It has outperformed by 4.00% the S&P500.

Artal Group Sa, which manages about $2.45B US Long portfolio, decreased its stake in Argenx Se by 70,000 shares to 200,000 shares, valued at $24.97 million in 2019Q1, according to the filing. It also reduced its holding in Madrigal Pharmaceuticals Inc by 35,000 shares in the quarter, leaving it with 35,000 shares, and cut its stake in Bank Amer Corp (Call) (NYSE:BAC).

More notable recent Acceleron Pharma Inc. (NASDAQ:XLRN) news were published by: Seekingalpha.com which released: “Acceleron Pharma Q2 2019 Earnings Preview – Seeking Alpha” on August 04, 2019, also Seekingalpha.com with their article: “Acceleron prices stock offering – Seeking Alpha” published on January 16, 2019, Seekingalpha.com published: “Acceleron Pharma Q4 2018 Earnings Preview – Seeking Alpha” on February 26, 2019. More interesting news about Acceleron Pharma Inc. (NASDAQ:XLRN) were released by: Seekingalpha.com and their article: “Acceleron bails on early-stage candidate; shares down 4% after hours – Seeking Alpha” published on April 04, 2019 as well as Seekingalpha.com‘s news article titled: “Acceleron co-founder bids adieu – Seeking Alpha” with publication date: June 10, 2019.

Acceleron Pharma Inc. (NASDAQ:XLRN) Ratings Coverage

Among 5 analysts covering Acceleron Pharma (NASDAQ:XLRN), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Acceleron Pharma has $78 highest and $4500 lowest target. $60.40’s average target is 34.16% above currents $45.02 stock price. Acceleron Pharma had 10 analyst reports since February 26, 2019 according to SRatingsIntel. H.C. Wainwright maintained it with “Buy” rating and $67 target in Tuesday, March 5 report. The firm has “Equal-Weight” rating by Barclays Capital given on Friday, May 3. The firm has “Overweight” rating by JP Morgan given on Tuesday, August 6. H.C. Wainwright maintained the stock with “Buy” rating in Tuesday, February 26 report. The company was reinitiated on Wednesday, May 29 by Goldman Sachs.

Acceleron Pharma Inc. (NASDAQ:XLRN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.